Naturex Reports Excellent Sales Growth and Good Operating Performances
date:Apr 02, 2014
act of Group restructuring measures (1.3% of sales) and revenue growth, in particular for Toll manufacturing activities.

External charges increased (+12.0%) in response to growth in sales, reinforced research and the headquarters' extension.

Recurring EBITDA amounted to 53 million, up from 51.1 million in 2012 or 3.8% with a recurring EBITDA margin at 16.5%.

Current operating income, remained largely stable in relation to the prior year at 35.3 million r
6/15 next page prev page home page last page
go back |  refresh |  WAP home |  Web page version  | login
07/20 01:31